We previously employed the same mild Taiwanese model in a preclinical study to first demonstrate the in vivo efficacy of nusinersen, the only approved drug to treat SMA, in which, an efficient correction of SMN2 splicing and rescue of tissue necrosis, a prominent phenotypic feature of this model, were achieved27,52. Here, SMN2 is linked to proximal spinal muscular atrophy.